By FMTeam In the southern part of the country, Amrutanjan Healthcare is one company that is doing phenomenally well right now, and it has been at it since 1893, actually. Though in India right now, not a lot of people know about their impressive works, so we’re here with this brief post about their net worth, their ownership, the ceo position, and their head office.
| Company/Brand name | Amrutanjan Health Care Limited |
| Establishment year | 1893 |
| Country of origin (headquarters) | India (Chennai, Tamil Nadu) |
| Owner/Founder | Public company; Founder: K. Nageswara Rao |
| CEO Name | S. Sambhu Prasad (Chairman & Managing Director) |
| Industry | Healthcare and OTC consumer products |
| Net worth | ₹288.49 crore (FY24 shareholders’ equity) |
| Total revenue in 2024 | ₹421.23 crore (FY22 revenue from operations) |
About the Company
Amrutanjan has been more like another name for fast headache relief since it launched its famous analgesic balm in 1893. In the subsequent years, the company has grown and diversified its product range but maintained its central promise of “fast relief.” Amrutanjan, apart from its timeless balm, presently presents newer product lines like Comfy (women’s hygiene) and Electro+ (hydration drinks). And just so you know, their main or head office is down there in Mylapore, Chennai.
Current Status
Amrutanjan Healthcare is a publicly traded company located in Chennai and has its manufacturing units spread across Tamil Nadu and Telangana, too. The company has matured well in FY24 and FY25 by gradually widening its scope of business in various categories like pain relief, women’s hygiene, and hydration beverages. Besides, its products have become available through quick-commerce and online platforms, which is another big plus point.
Recent Updates and Future Outlook
Amrutanjan, for the quarter ended June 2025 (Q1 FY26), net sales were around ₹94 crores, which is almost 12% higher year-on-year. The profit after tax was at ₹8.31 crores. The company is enjoying the positive effects of and therefore extends the growth trend, which was created in FY25 and was mainly driven by the increased sales of the pain relief and hygiene segments.